Clinical trial design for HMI-203 investigational gene therapy for mucopolysaccharidosis type II (MPS II) informed by cross-correction potential and KOL input

被引：0
|
作者：
Gingras, Jacinthe [1 ]
Haroldson, Jeff [1 ]
Smith, Laura J. [1 ]
Patel, Kruti [1 ]
Salstrom, Jen [1 ]
Jordan, Julie [1 ]
Cohn, Gabriel M. [1 ]
Francone, Omar [1 ]
Seymour, Albert [1 ]
机构：
[1] Homol Med, Bedford, MA USA
来源：
MOLECULAR GENETICS AND METABOLISM | 2022年 / 135卷 / 02期
关键词：
D O I：
10.1016/j.ymgme.2021.11.108
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
93
引用
收藏
页码：S46 / S46
页数：1
相关论文
共 20 条
  • [1] HMI-203: Investigational gene therapy for mucopolysaccharidosis type II (MPS II), or Hunter syndrome
    Patel, Kruti
    Smith, Laura
    Gingras, Jacinthe
    Tzianabos, Alec
    Schulman, Lindsay
    Zhivich, Victor
    Kivaa, Monicah
    Faulkner, Deiby
    Sengooba, Arnold
    Seabrook, Tania
    Behmoiras, Liana
    Dollive, Serena
    Avila, Nancy
    Zhao, Jingyan
    White, Yvonne
    Newman, Jenn
    Woodcock, Steve
    Smith, Sean
    Francone, Omar
    Seymour, Albert
    MOLECULAR GENETICS AND METABOLISM, 2021, 132 (02) : S82 - S82
  • [2] HMI-203: Gene therapy developmental candidate for mucopolysaccharidosis type II (MPS II), or Hunter syndrome
    Patel, Kruti
    Smith, Laura
    Seabrook, Tania
    Tzianabos, Alec
    Schulman, Lindsay
    Zhivivh, Victor
    Kivaa, Monicah
    Faulkner, Deiby
    Sengooba, Arnold
    Behmoiras, Liana
    Newman, Jennifer
    Dollive, Serena
    Avila, Nancy
    Zhao, Jingyan
    White, Yvonne
    Woodcock, Steve
    Smith, Sean
    Francone, Omar
    Gingras, Jacinthe
    Seymour, Albert
    MOLECULAR GENETICS AND METABOLISM, 2021, 132 : S147 - S147
  • [3] Long-Term Expression of HMI-203: Investigational Gene Therapy Candidate for Mucopolysaccharidosis Type II (MPS II), or Hunter Syndrome
    Smith, Laura
    Patel, Kruti
    Gingras, Jacinthe
    Tzianabos, Alec
    Schulman, Lindsay
    Zhivich, Victor
    Kivaa, Monicah
    Faulkner, Deiby
    Sengooba, Arnold
    Behmoiras, Liana
    Seabrook, Tania
    Dollive, Serena
    Avila, Nancy
    Zhao, Jingyan
    White, Yvonne
    Newman, Jenn
    Woodcock, Steve
    Smith, Sean
    Francone, Omar
    Seymour, Albert
    MOLECULAR THERAPY, 2021, 29 (04) : 247 - 247
  • [4] Summary of nonclinical data for gene therapy developmental candidate HMI-203 for mucopolysaccharidosis type II (MPS II, or Hunter syndrome)
    Smith, Laura J.
    Patel, Kruti
    Seabrook, Tania
    Schulman, Lindsay
    Zhivich, Victor
    Kivaa, Monicah
    Behmoiras, Liana
    Tzianabos, Alec
    Faulkner, Deiby
    Sengooba, Arnold
    Avila, Nancy
    Newman, Jennifer
    Zhao, Jingyan
    Woodcock, Steve
    Klem, Thomas
    Smith, Sean
    Seymour, Albert
    Francone, Omar
    Gingras, Jacinthe
    MOLECULAR GENETICS AND METABOLISM, 2022, 135 (02) : S113 - S114
  • [5] Patient and physician perspectives inform clinical trial design for a single intravenous dose of HMI-203, a gene therapy candidate for adults with mucopolysaccharidosis type II (MPS II, Hunter syndrome)
    Haroldson, Jeffrey
    Witalisz, Cj
    Mayfield, Cara
    Ellinwood, N. Matthew
    Urdaneta, Leslie
    Martin, Rick
    Cohn, Gabriel
    MOLECULAR GENETICS AND METABOLISM, 2022, 135 (02) : S54 - S55
  • [6] Blood-brain-barrier crossing leads to long term efficacy in the CNS of HMI-203: Gene therapy development candidate for Mucopolysaccharidosis Type II (MPS II), or Hunter Syndrome
    Smith, L.
    Patel, K.
    Gingras, J.
    Tzianabos, A.
    Seabrook, T.
    Kivaa, M.
    Schulman, L.
    Zhivich, V.
    Faulkner, D.
    Sengooba, A.
    Behmoiras, L.
    Dollive, S.
    Avila, N.
    Zhao, J.
    White, Y.
    Newman, J.
    Woodcock, S.
    Smith, S.
    Francone, O.
    Seymour, A.
    HUMAN GENE THERAPY, 2021, 32 (19-20) : A52 - A52
  • [7] Gene therapy for cross-correction of somatic organs and the CNS in mucopolysaccharidosis II in rodents and non-human primates
    Chen, Nancy
    Ehmann, David E.
    Crooker, Robert
    Derakhchan, Katayoun
    Fang, Xiaodong
    Felice, Brian
    Galbreath, Elizabeth J.
    Glaus, Charles
    Gu, Hongbo
    Huang, Yan
    Li, Christine
    Li, Xing
    Liu, Nan
    Palmieri, Kathleen
    Simic, Damir
    Sypek, Joseph
    Thompson, Susan
    Winkelmann, Christopher T.
    Choi, Vivian W.
    MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT, 2023, 29 : 286 - 302
  • [8] CAMPSIITET Phase I/II/III: An interim clinical study update of RGX-121, an investigational gene therapy for the treatment of neuronopathic mucopolysaccharidosis type II (MPS II)
    Pisani, Laura
    Ficicioglu, Can
    Harmatz, Paul
    Giugliani, Roberto
    Rajan, Deepa
    Hagood, Joseph
    Fiscella, Michele
    Yang, Lin
    Gilmor, Michelle
    Cho, Yoonjin
    Mulatya, Caroline
    Phillips, Dawn
    Boulos, Nidal
    Falabella, Paulo
    MOLECULAR GENETICS AND METABOLISM, 2024, 141 (04)
  • [9] CAMPSIITETM phase I/II/III: An interim clinical study update of RGX-121, an investigational gene therapy for the treatment of neuronopathic mucopolysaccharidosis type II (MPS II)
    Harmatz, Paul
    Ficicioglu, Can
    Giugliani, Roberto
    Rajan, Deepa
    Hagood, Joseph
    Fiscella, Michele
    Yang, Lin
    Gilmor, Michelle
    Cho, Yoonjin
    Mulatya, Caroline
    Phillips, Dawn
    Boulos, Nidal
    Falabella, Paulo
    Pisani, Laura
    MOLECULAR GENETICS AND METABOLISM, 2024, 141 (02)
  • [10] CAMPSIITET Phase I/II/III: An Interim Clinical Study Update of RGX-121, an Investigational Gene Therapy for the Treatment of Neuronopathic Mucopolysaccharidosis Type II (MPS II)
    Pisani, Laura
    Giugliani, Roberto
    Ficicioglu, Can
    Harmatz, Paul
    Rajan, Deepa
    Hagood, Joseph
    Fiscella, Michele
    Yang, Lin
    Gilmor, Michelle
    Cho, Yoonjin
    Mulatya, Caroline
    Phillips, Dawn
    Boulos, Nidal
    Falabella, Paulo
    MOLECULAR THERAPY, 2024, 32 (04) : 26 - 27
12